Abstract
A pooled subanalysis of the efficacy of certolizumab pegol in patients with self-reported psoriatic arthritis in ongoing phase 3 psoriasis studies (CIMPASI-1, CIMPASI-2, and CIMPACT)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
